/C O R R E C T I O N -- Life Technologies Corporation/

            /C O R R E C T I O N -- Life Technologies Corporation/

PR Newswire

CARLSBAD, Calif., Nov. 1, 2012

In the news release, Life Technologies Announces Third Quarter 2012 Results,
issued 01-Nov-2012 by Life Technologies Corporation over PR Newswire, we are
advised by the company that on November 1, 2012 the Company received an
unfavorable verdict in its litigation with Enzo Biochem. The Company does not
expect this verdict to have a material impact on its business going forward as
this intellectual property was held by Enzo Biochem during the period
1998-2004 and the patent expired in 2004. Although the Company strongly
disagrees with the verdict and intends to vigorously challenge it in the trial
court and on appeal, the Company has recorded a charge of $48.5 million
related to the lawsuit in the third quarter of fiscal 2012. As a result, the
Company's previously reported third quarter 2012 GAAP diluted earnings per
share will decrease $0.18 per share from $0.55 per share to $0.37 per share.
The verdict did not impact the non-GAAP diluted earnings per share. The
Company has provided revised financial statements and reconciliations between
GAAP and Non-GAAP Net Income. The complete, corrected release follows:

  Life Technologies Announces Third Quarter 2012 Results

    Revenue of $911 million

    GAAP earnings per share (EPS) of $0.37, or $0.92 on a non-GAAP basis

    Free Cash Flow of $177 million

    Company repurchased $208 million of shares in the third quarter, total of
    $535 million year-to-date

CARLSBAD, Calif., Nov. 1, 2012 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced results for its third quarter ended September
30, 2012. Revenue for the third quarter was $911 million, a decrease of 1.9
percent over the $929 million reported for the third quarter of 2011.
Excluding the impact of currency, revenue growth for the quarter was 1.4
percent compared to the same period of the prior year.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

"Our third quarter performance came in stronger than our expectations driven
by a significant increase in Ion Torrent platform sales, as well as increased
sales in our research consumables and forensics businesses," said Gregory T.
Lucier, chairman and chief executive officer of Life Technologies. "During the
quarter, we made solid progress in expanding our operations and footprint in
high growth and emerging markets, including entering into strategic
partnerships for companion diagnostics, building the foundation for our
Medical Sciences business and acquiring distributors in China and Chile. We
achieved important milestones with several highly anticipated launches
including the Ion Proton^™ System, a platform whose speed, ease of use and
affordability will democratize genome sequencing, and our Pervenio^™ Lung RS
test service, the first of its kind molecular test to identify early-stage
lung cancer patients who are at high risk of reoccurrence following surgery."

"We continue to demonstrate our commitment to returning capital to
shareholders by repurchasing an additional $208 million worth of shares in the
third quarter, bringing our year-to-date total to $535 million. Based on our
performance year-to-date and end market assumptions, we are tightening the
full year guidance range by increasing the bottom end by $0.05 and are now
expecting non-GAAP earnings per share of $3.95 to $4.00."

Life Technologies reported current quarter results compared to the quarter
ended September 30, 2011. Results are non-GAAP unless indicated otherwise. A
full reconciliation of the non-GAAP measures to GAAP can be found in the
tables of today's press release.

Analysis of Third Quarter 2012 Results

  oThird quarterrevenue decreased 1.9 percent over the prior year. Revenue
    growth without the impact from currency was 1.4 percent.
  oGross margin in the third quarterwas 65.6 percent, approximately 50 basis
    points lower than the same period of the prior year primarily driven by
    unfavorable currency rates.
  oOperating margin was 28.0 percent in the third quarter, approximately 140
    basis points lower than the same period of the prior year. Operating
    margin contraction was primarily due to unfavorable currency rates and
    increased investments in Greater China and Medical Sciences.
  oThird quarter tax rate was27.3 percent.
  oThird quarter EPS was $0.92.
  oDiluted weighted shares outstandingwere177.3 million in the third
    quarter, a decrease of 9.6 million shares over the prior year. The
    decrease was a result of the continuation of the company's share
    repurchase program, partially offset by shares issued for employee stock
    plans. The company repurchased $208 million or 4.4 million shares in the
    third quarter.
  oCash flow from operating activities for the third quarter was $197
    million. Third quarter capital expenditures were $20 million, resulting in
    free cash flow of $177 million. The company ended the quarter with $299
    million in cash and short-term investments.

Business Group Highlights

  oResearch Consumables revenue was $384 million, a decrease of 3 percent
    compared to the prior year. Excluding the impact from currency, revenue
    for the business group grew 1 percent, primarily as a result of growth in
    our cell culture products, sample prep products and benchtop instruments.
  oGenetic Analysis revenue was $353 million in the third quarter, a decrease
    of 1 percent over the same period last year. Excluding the impact from
    currency, revenue increased 2 percent primarily as a result of increased
    sales of the Ion Torrent platform, including the Ion Proton^™ System and
    the Ion PGM^™ benchtop instruments, offset by an expected decline in
    SOLiD^® instrument sales and lower sales of CE instruments, primarily due
    to one-time orders in the prior year quarter and the timing of sales.
  oApplied Sciences revenue was $174 million in the third quarter, flat
    compared to the same period last year. Excluding the impact from currency,
    revenue increased 3 percent, primarily due to forensics and higher sales
    of qPCR applied sciences instruments, offset by lower sales of CE
    instruments due to one-time orders in the prior year quarter, and an
    expected decline in BioProduction sales, which tend to fluctuate quarter
    to quarter.
  oRegional revenue growth rates excluding currency for the quarter compared
    to the same quarter of the prior year were as follows: the Americas
    declined 1 percent, Europe grew 2 percent, Asia Pacific grew 10 percent
    and Japan grew 4 percent.

Fiscal Year 2012 Outlook

Subject to the risk factors detailed in the Safe Harbor Statement section of
this release, the company is updating its guidance. The company's updated 2012
guidance is for organic revenue growth of approximately 2 percent over 2011
revenues of $3.7 billion. Additionally, the company is tightening the
previously provided range by increasing the bottom by $0.05 and is now
expecting non-GAAP earnings per share of $3.95 to $4.00. The company will
provide further detail on its business outlook during the webcast today.

The Ion Proton^™ System is for Research Use Only and not intended for use in
diagnostic procedures.

Webcast Details

The company will discuss its financial and business results as well as its
business outlook on its webcast at4:30 PM ET today.This webcast will contain
forward-looking information.The webcast will include a discussion of
"non-GAAP financial measures" as that term is defined in Regulation G.For
actual results, the most directly comparable GAAP financial measures and
information reconciling these non-GAAP financial measures to the company's
financial results determined in accordance with GAAP, as well as other
material financial and statistical information to be discussed on the webcast
will be posted at the company's investor relations website at
https://ir.lifetechnologies.com. The webcast can be accessed through the
investor relations page of the company's website at
https://ir.lifetechnologies.com/events.cfm. A replay of the webcast will be
available on the company's website through Thursday, November 22, 2012.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied Biosystems®,
Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life
Technologies employs approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of $3.7 billion in 2011. Visit us at our website:
http://www.lifetechnologies.com.

Safe Harbor Statement

Certain statements contained in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, and Life Technologies intends that such forward-looking statements be
subject to the safe harbor created thereby.Forward-looking statements may be
identified by words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "will," or words of similar meaning and
include, but are not limited to, statements about the expected future business
and financial performance of the company. Such forward-looking statements
include, but are not limited to, statements relating to financial projections,
including revenue and pro forma EPS projections; success of acquired
businesses, including cost and revenue synergies; development and increased
flow of new products; leveraging technology and personnel; advanced
opportunities and efficiencies; opportunities for growth; expectations of
prospective new standards, new delivery platforms, and new selling
specialization and effectiveness; and corporate strategy and performance.A
number of the matters discussed in this press release and presentation that
are not historical or current facts deal with potential future circumstances
and developments, including future research and development plans. The
discussion of such matters is qualified by the inherent risks and
uncertainties surrounding future expectations generally and other factors that
could cause actual results to differ materiallyfrom future results expressed
or implied by such forward-looking statements. Such risks and uncertainties
include, but are not limited to: volatility of the financial markets; and the
risks that are described from time to time in Life Technologies' reports filed
with the SEC.This press release and presentation speaks only as of its date,
and the company disclaims any duty to update the information herein.

Non-GAAP Measurements

This press release includes certain financial information which constitutes
"non-GAAP financial measures" as defined by the SEC.The GAAP measures which
are most directly comparable to these measures, as well as a reconciliation of
these measures with the most directly comparable GAAP measures, can be found
on the investor relations portion of the company's website at
www.lifetechnologies.com.

Investor and Financial Contact
Carol Cox
Investor Relations
(760) 603-7208
ir@lifetech.com

LIFE TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
                                              For the three    For the three
                                              months           months
(in thousands, except per share data)         ended September  ended September
                                              30, 2012         30, 2011
(unaudited)
Revenues                                      $            $      
                                              911,183         928,198
Cost of revenues                              361,571          315,062
Purchased intangibles amortization            71,126           73,901
                  Gross profit                478,486          539,235
Gross margin                                  52.5%            58.1%
Operating expenses:
     Selling, general and administrative      270,565          251,832
     Research and development                 84,811           103,856
     Business consolidation costs             10,571           23,126
              Total operating expenses        365,947          378,814
                  Operating income            112,539          160,421
Operating margin                              12.4%            17.3%
     Interest income                          436              919
     Interest expense                         (29,291)         (37,992)
     Other expense, net                       (2,781)          (3,039)
              Total other expense, net        (31,636)         (40,112)
Income from operations before provision for
 income taxes                             80,903           120,309
Income tax provision                          (15,301)         (24,335)
                  Net income                  65,602           95,974
                  Net loss attributable to    255              297
                  non-controlling interests
                  Net income attributable to  $            $      
                  controlling interest        65,857          96,271
Effective tax rate                           18.9%            20.2%
Add back interest expense for subordinated
 debt, net of tax                          -                650
Numerator for diluted earnings
 per share                                   $            $      
                                              65,857          96,921
Earnings per common share:
     Basic earnings per share attributable to $          $       
     controlling interest                     0.38             0.54
     Diluted earnings per share attributable  $          $       
     to controlling interest                  0.37             0.52
Weighted average shares used in per share
calculation:
     Basic                                    174,044          179,859
     Diluted                                  177,258          186,812

LIFE TECHNOLOGIES CORPORATION
ITEMIZED RECONCILIATION BETWEEN
GAAP AND NON-GAAP NET INCOME
                                       For the three       For the three
                                       months              months
                                       ended               ended
(in thousands, except per share data)  September 30,       September 30,
                                       2012                2011
(unaudited)
GAAP net income                       $               $    95,974
                                       65,602
 Non-GAAP revenue adjustments
              Purchase accounting      193                 644
              related adjustments
              Charges on a             -                   (101)
              discontinued product
 Total Non-GAAP revenue adjustments    193            ^(1) 543            ^(1)
 Non-GAAP cost of revenues and
 purchased intangible adjustments
              Purchased intangibles    71,126              73,901
              amortization
              Purchase accounting      -                   (183)
              related adjustments
              Legal judgment           48,500              -
 Total Non-GAAP cost of revenues and   119,626        ^(2) 73,718         ^(2)
 purchased intangible adjustments
 Non-GAAP Operating Expense
 Adjustments:
              Purchase accounting      1,019               15,367
              related adjustments
              Business consolidation   10,571              23,126
              costs
              Legal settlement         11,400              -
 Total Non-GAAP Operating Expense      22,990         ^(3) 38,493         ^(3)
 Adjustments
 Non-GAAP Other Expense Adjustments:
              Noncash interest expense -                   6,572
              charges
 Total Non-GAAP Other Expense          -                   6,572          ^(4)
 Adjustments
 Non-GAAP Income Tax Provision
 Adjustments:
              Income tax adjustments   (45,740)            (40,612)
 Total Non-GAAP Income Tax Provision   (45,740)       ^(5) (40,612)       ^(5)
 Adjustments
Non-GAAP Net Income                    $   162,671      $   174,688
 Non-GAAP loss attributable to         255            ^(6) 193            ^(6)
 controlling interest
Non-GAAP Net Income Attributable to    $   162,926      $   174,881
Controlling Interest
Add back of interest expense for       -                   32
subordinated debt, net of tax
Non-GAAP Numerator for diluted         $   162,926      $   174,913
earnings per share
Non-GAAP Earnings per common share:
 Basic earnings per share attributable $             $     
 to controlling interest               0.94                0.97
 Diluted earnings per share            $             $     
 attributable to controlling interest  0.92                0.94
Weighted average shares used in per
share calculation:
 Basic                                 174,044             179,859
 Diluted                               177,258             186,812

Summary of Reconciliation between GAAP and Non-GAAP Net Income
        For the three months ended September 30, 2012, Non-GAAP earnings
        resulted in total revenue of $911.4 million, gross profit of $598.3
        million with gross margin of 65.6%, operating profit of $255.3 million
        with operating margin of 28.0%, and an income tax provision of $61.0
        million with the Non-GAAP effective tax rate of 27.3% with the above
        adjustments.
        For the three months ended September 30, 2011, Non-GAAP earnings
        resulted in total revenue of $928.7 million, gross profit of $613.5
        million with gross margin of 66.1%, operating profit of $273.2 million
        with operating margin of 29.4%, and an income tax provision of $64.9
        million with the Non-GAAP effective tax rate of 27.1% with the above
        adjustments.
Notes
        Add back purchased deferred revenue of $0.2 million and $0.6 million
^(1)    for the three months ended September 30, 2012 and 2011, respectively,
        and adjust revenue related to returns of a discontinued product of
        $0.1 million for the three months ended September 30, 2011.
        Add back amortization of purchased intangibles of $71.1 million and
        $73.9 million for the three months ended September 30, 2012 and 2011,
^(2)    respectively. Add back the legal judgment of $48.5 million for the
        three months ended September 30, 2012, and adjust charges for a
        contingent consideration remeasurement of $0.2 million for the three
        months ended September 30, 2011.
        Add back depreciation of purchase accounting property, plant, and
        equipment revaluation of $1.0 million and $1.7 million, and business
        consolidation costs including restructuring and integrating acquired
        entities, aligning acquired and existing operations through business
        transformation activities and costs associated with divesting entities
^(3)    of $10.6 million and $23.1 million for the three months ended
        September 30, 2012 and 2011, respectively. Add back legal settlement
        of $11.4 million for the three months ended September 30, 2012, and
        add back purchase accounting contingent consideration fair value
        adjustment of $13.7 million for the three months ended September 30,
        2011.
        Add back charges related to non-cash interest expense for senior
^(4)    convertible debts of $5.1 million and imputed finance charge of $1.5
        million associated with contingent consideration on business
        acquisitions for the three months ended September 30, 2011.
        Non-GAAP tax adjustment due to the exclusion of the aforementioned
        business combination related charges, non cash charges, and one-time
^(5)    costs which are not indicative of the profitability or cash flows of
        the Company's ongoing or future operations. These deductions produce a
        GAAP only tax benefit which is added back for Non-GAAP presentation.
        Non-GAAP net loss attributable to non-controlling interest, net of tax
^(6)    benefit, adjusted for noncash charges for purchase accounting
        property, plant, and equipment revaluation, net of tax benefit.
        The Company reports Non-GAAP results which excludes costs that are not
        indicative of the profitability or cash flows of the Company's ongoing
        or future operations. Such costs are restructuring cost, business
        transformation expenses, amortization and depreciation of deferred
        revenue, intangibles assets, and fixed assets, and revaluation charges
        for inventories, contingent consideration liabilities, asset
        impairments, and in process research and development expenses,
        incurred as a result of business combinations as well as the impact
        from the divestiture and discontinuance of product lines. The Company
        also excludes noncash interest expense associated with convertible
        debt bifurcation and noncash charges associated with non-controlling
        interests. In addition, the Company excludes one-time costs including
        the early repayment of debt and the associated impacts, and the impact
        of certain settlements in order to provide a supplemental comparison
        of the results of operations.



LIFE TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
                                             For the nine     For the nine
                                             months           months
(in thousands, except per share data)        ended September  ended September
                                             30, 2012         30, 2011
(unaudited)
Revenues                                     $            $   2,765,227
                                             2,799,606
Cost of revenues                             1,003,611        955,840
Purchased intangibles amortization           219,192          226,527
               Gross profit                  1,576,803        1,582,860
Gross margin                                 56.3%            57.2%
Operating expenses:
  Selling, general and administrative        790,012          759,438
  Research and development                   258,225          287,723
  Business consolidation costs               34,266           56,468
          Total operating expenses           1,082,503        1,103,629
               Operating income              494,300          479,231
Operating margin                             17.7%            17.3%
  Interest income                            1,715            2,960
  Interest expense                           (94,266)         (123,911)
  Other expense, net                         (11,097)         (7,980)
          Total other expense, net           (103,648)        (128,931)
Income from operations before provision for
 income taxes                            390,652          350,300
Income tax provision                         (70,108)         (65,534)
               Net income                    320,544          284,766
               Net loss attributable to      305              658
               non-controlling interests
               Net income attributable to    $            $    285,424
               controlling interest          320,849
Effective tax rate                          17.9%            18.7%
Add back interest expense for subordinated
 debt, net of tax                         12               716
Numerator for diluted earnings
 per share                                  $            $    286,140
                                             320,861
Earnings per common share:
  Basic earnings per share attributable to   $         $      
  controlling interest                       1.81            1.59
  Diluted earnings per share attributable to $         $      
  controlling interest                       1.78            1.54
Weighted average shares used in per share
calculation:
  Basic                                      177,028          179,751
  Diluted                                    180,559          185,946

LIFE TECHNOLOGIES CORPORATION
ITEMIZED RECONCILIATION BETWEEN
GAAP AND NON-GAAP NET INCOME
                                         For the nine        For the nine
                                         months              months
                                         ended               ended
(in thousands, except per share data)    September 30,       September
                                         2012                30, 2011
(unaudited)
GAAP net income                         $                 $   
                                         320,544            284,766
     Non-GAAP revenue adjustments
               Purchase accounting       835                 2,375
               related adjustments
               Charges on a discontinued (457)               2,736
               product
     Total Non-GAAP revenue adjustments  378           ^(1)  5,111        ^(1)
     Non-GAAP cost of revenues and
     purchased intangible adjustments
               Purchased intangibles     219,192             226,527
               amortization
               Purchase accounting       -                   (1,555)
               related adjustments
               Charges on a discontinued -                   2,094
               product
               Legal judgement and
               settlement of historical  48,331              -
               portion of licensing
               dispute
     Total Non-GAAP cost of revenues and 267,523       ^(2)  227,066      ^(2)
     purchased intangible adjustments
     Non-GAAP Operating Expense
     Adjustments:
               Purchase accounting       2,869               20,886
               related adjustments
               Business consolidation    34,266              56,468
               costs
               Licensing and legal       10,467              -
               settlements
     Total Non-GAAP Operating Expense    47,602        ^(3)  77,354       ^(3)
     Adjustments
     Non-GAAP Other Expense Adjustments:
               Noncash interest expense  5,382               24,130
               charges
               Other expense             5,302               -
     Total Non-GAAP Other Expense        10,684        ^(4)  24,130       ^(4)
     Adjustments
     Non-GAAP Income Tax Provision
     Adjustments:
               Income tax adjustments    (128,868)           (122,610)
     Total Non-GAAP Income Tax Provision (128,868)     ^(5)  (122,610)    ^(5)
     Adjustments
Non-GAAP Net Income                      $                 $   
                                         517,863            495,817
     Non-GAAP loss attributable to       305           ^(6)  350          ^(6)
     controlling interest
Non-GAAP Net Income Attributable to      $                 $   
Controlling Interest                     518,168            496,167
Add back interest expense for            12                  98
subordinated debt, net of tax
Non-GAAP Numerator for diluted earnings  $                 $   
per share                                518,180            496,265
Non-GAAP Earnings per common share:
     Basic earnings per share            $             $     
     attributable to controlling         2.93                  2.76
     interest
     Diluted earnings per share          $             $     
     attributable to controlling         2.87                  2.67
     interest
Weighted average shares used in per
share calculation:
     Basic                               177,028             179,751
     Diluted                             180,559             185,946
Summary of Reconciliation between GAAP and Non-GAAP Net Income
     For the nine months ended September 30, 2012, Non-GAAP earnings resulted
     in total revenue of $2.8 billion, gross profit of $1.8 billion with gross
     margin of 65.9%, operating profit of $809.8 million with operating margin
     of 28.9%, and an income tax provision of $199.0 million with the Non-GAAP
     effective tax rate of 27.8% with the above adjustments.
     For the nine months ended September 30, 2011, Non-GAAP earnings resulted
     in total revenue of $2.8 billion, gross profit of $1.8 billion with gross
     margin of 65.5%, operating profit of $788.8 million with operating margin
     of 28.5%, and an income tax provision of $188.1 million with the Non-GAAP
     effective tax rate of 27.5% with the above adjustments.
Notes
     Add back purchased deferred revenue of $0.8 million and adjust for
     revenue related to a discontinued product of $0.5 million for the nine
^(1) months ended September 30, 2012. Add back purchased deferred revenue of
     $2.4 million and revenue related to returns of a discontinued product of
     $2.7 million for the nine months ended September 30, 2011.
     Add back amortization of purchased intangibles of $219.2 million and a
     legal judgment of $48.5 million partially offset by $0.2 million related
     to the historical portion of the settlement of licensing disputes for the
     nine months ended September 30, 2012. Add back amortization of purchased
^(2) intangibles of $226.5 million, charges for inventory reserves related to
     a discontinued product of $2.1 million, and purchase accounting related
     cost of revenue revaluation of $0.5 million which was offset by
     contingent consideration revaluation of $2.1 million for the nine months
     ended September 30, 2011.
     Add back depreciation of purchase accounting property, plant, and
     equipment revaluation of $2.9 million, and add back legal settlement of
     $11.4 million and adjust for compensation cost of $0.9 million related to
     the historical portion of the settlement of a licensing dispute for the
     nine months ended September 30, 2012. Add back depreciation of purchase
     accounting property, plant, and equipment revaluation of $5.7 million,
^(3) purchase accounting contingent consideration fair value adjustment of
     $13.7 million and accelerated compensation expense related to business
     acquisitions of $1.5 million for the nine months ended September 30,
     2011. Add back business consolidation costs including restructuring and
     integrating acquired entities, aligning acquired and existing operations
     through business transformation activities and costs associated with
     divesting entities of $34.3 million and $56.5 million for the nine months
     ended September 30, 2012 and 2011, respectively.
     Add back charges associated with a divestiture activity of $5.3 million,
     charges related to non-cash interest expense for senior convertible debts
     of $1.7 million and the extinguishment of a line of credit facility of
^(4) $3.7 million for the nine months ended September 30, 2012. Add back
     charges related to non-cash interest expense for senior convertible debts
     of $19.5 million and charges for imputed finance charge of $4.6 million
     associated with contingent consideration on business acquisitions for the
     nine months ended September 30, 2011.
     Non-GAAP tax adjustment due to the exclusion of the aforementioned
     business combination related charges, non cash charges, and one-time
^(5) costs which are not indicative of the profitability or cash flows of the
     Company's ongoing or future operations. These deductions produce a GAAP
     only tax benefit which is added back for Non-GAAP presentation.
     Non-GAAP net loss attributable to non-controlling interest, net of tax
^(6) benefit, adjusted for noncash charges for purchase accounting property,
     plant, and equipment revaluation, net of tax benefit.
     The Company reports Non-GAAP results which excludes costs that are not
     indicative of the profitability or cash flows of the Company's ongoing or
     future operations. Such costs are restructuring cost, business
     transformation expenses, amortization and depreciation of deferred
     revenue, intangibles assets, and fixed assets, and revaluation charges
     for inventories, contingent consideration liabilities, asset impairments,
     and in process research and development expenses, incurred as a result of
     business combinations as well as the impact from the divestiture and
     discontinuance of product lines. The Company also excludes noncash
     interest expense associated with convertible debt bifurcation and noncash
     charges associated with non-controlling interests. In addition, the
     Company excludes one-time costs including the early repayment of debt and
     the associated impacts, and the impact of certain settlements in order to
     provide a supplemental comparison of the results of operations.

LIFE TECHNOLOGIES CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                        For the nine months
                                        ended September 30,
(in thousands)(unaudited)               2012                 2011
Net income                              $               $     284,766
                                        320,544
        Add back amortization and
         share-based compensation    292,918              289,912
        Add back depreciation           93,617               90,988
        Balance sheet changes           (42,539)             (153,355)
        Other noncash adjustments       (107,755)            (19,104)
Net cash provided by operating          556,785              493,207
activities
        Capital expenditures            (68,385)             (65,779)
Free cash flow                          488,400              427,428
Net cash used in investing activities   (72,057)             (48,645)
Net cash used in financing activities   (980,524)            (601,228)
Effect of exchange rate changes on cash (420)                3,092
Net decrease in cash and cash           $               $    (219,353)
equivalents                             (564,601)

LIFE TECHNOLOGIES CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
                                        September 30,           December 31,
(in thousands)                          2012                     2011
ASSETS                                  (unaudited)
Current assets:
 Cash and short-term investments        $        299,270  $      
                                                                 881,994
 Trade accounts receivable, net of      644,579                  636,998
 allowance for doubtful accounts
 Inventories                            400,680                  377,866
 Prepaid expenses and other current     251,160                  196,759
 assets
  Total current assets              1,595,689                2,093,617
Long-term assets                        6,962,346                7,094,346
  Total assets                      $      8,558,035   $    
                                                                 9,187,963
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
 Current portion of long-term debt      $        253,200  $      
                                                                 450,839
 Short-term borrowings                  140,000                  -
 Accounts payable, accrued expenses and 728,468                  1,045,467
 other current liabilities
  Total current liabilities         1,121,668                1,496,306
Long-term debt                          2,061,280                2,297,653
Other long-term liabilities             760,586                  794,778
Stockholders' equity                    4,614,501                4,599,226
  Total liabilities and              $      8,558,035   $    
 stockholders' equity                                            9,187,963

SOURCE Life Technologies Corporation

Website: http://www.lifetechnologies.com
 
Press spacebar to pause and continue. Press esc to stop.